Skip to main content
SpringerLink
Log in

Effects of drug-drug interactions involving oral antihyperglycaemics are, with the exception of hypoglycaemia, mostly clinically unimportant

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Scheen AJ. Drug Interaction of clinical importance with antihypertensive agents: an update. Drug Saf 2005; 28(7): 601–31

    Article  PubMed  CAS  Google Scholar 

  2. Marathe PH, Arnold ME, Meeker J, et al. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol 2000; 40: 1494–502

    PubMed  CAS  Google Scholar 

  3. UKPDS Prospective Diabetes Study Group. Effects of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65

    Article  Google Scholar 

  4. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558–60

    Article  PubMed  CAS  Google Scholar 

  5. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24: 151–8

    Article  PubMed  CAS  Google Scholar 

  6. Mannucci E, Monami M, Masotti G, et al. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004; 20: 44–7

    Article  PubMed  CAS  Google Scholar 

  7. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333–43

    Article  PubMed  CAS  Google Scholar 

  8. Hanefeld M, Brunetti P, Schemathaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141–7

    Article  PubMed  CAS  Google Scholar 

  9. Di Cicco RA, Allen A, Carr A, et al. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol 2000; 40: 1280–5

    PubMed  Google Scholar 

  10. Kleist P, Ehrlich A, Suzuki Y, et al. Concomitant administration of the α-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol 1997; 53: 149–52

    Article  PubMed  CAS  Google Scholar 

  11. Scheen AJ, Ferreira Alves de Magalhaes C, Salvatore T, et al. Reduction of the acute bioavailability of metformin by the α-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994; 24Suppl. 3: 50–4

    PubMed  CAS  Google Scholar 

  12. Miller AK, Inglis AM, Thompson Culkin K, et al. The effect of acarbose on the pharmacokinetics of rosiglitazone. Eur J Clin Pharmacol 2001; 57: 105–9

    Article  PubMed  CAS  Google Scholar 

  13. Raskin P, Klaff L, McGill S, et al. Efficacy and safety of combination therap: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26: 2063–8

    Article  PubMed  CAS  Google Scholar 

  14. Hirshberg Y, Karara AH, Pietri AO, et al. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000; 23: 349–53

    Article  Google Scholar 

  15. McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004; 43: 97–120

    Article  PubMed  CAS  Google Scholar 

  16. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366(9493): 1279–89

    Article  PubMed  CAS  Google Scholar 

  17. Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003; 43: 649–60

    PubMed  CAS  Google Scholar 

  18. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004; 27: 247–55

    Article  PubMed  Google Scholar 

  19. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 1994; 11: 137–44

    Article  PubMed  CAS  Google Scholar 

  20. Herings RM, de Boer A, Stricker BH, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195–8

    Article  PubMed  CAS  Google Scholar 

  21. Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005 Aug; 22(8): 986–93

    Article  PubMed  CAS  Google Scholar 

  22. Appel S, Rufenacht T, Kalafsky G, et al. Lack of interaction between fluvastatin and oral hypoglycaemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 1995; 76: 29A–32A

    Article  PubMed  CAS  Google Scholar 

  23. Niemi M, Neuvonen PJ, Kivisto KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 70: 439–45

    Article  PubMed  CAS  Google Scholar 

  24. Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003; 46: 347–51

    Article  PubMed  CAS  Google Scholar 

  25. Jones NP, Mather RA, Sautter M. Rosiglitazone treatment does not impair the triglyceride-lowering activity of fibrates in patients with type 2 diabetes mellitus [abstract]. Diabetes 2000; 49Suppl. 1: A359, 1507-PO

    Google Scholar 

  26. Niemi M, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001; 69: 400–6

    Article  PubMed  CAS  Google Scholar 

  27. Park JY, Kim KA, Park PW, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 2003; 74: 334–40

    Article  PubMed  CAS  Google Scholar 

  28. Niemi M, Backman JT, Neuvonen M, et al. Effect of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 69: 194–200

    Article  PubMed  CAS  Google Scholar 

  29. Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol 1993; 35: 321–3

    Article  PubMed  CAS  Google Scholar 

  30. Somogyi A, Stockley C, Keal J. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23: 545–51

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Effects of drug-drug interactions involving oral antihyperglycaemics are, with the exception of hypoglycaemia, mostly clinically unimportant. Drugs Ther. Perspect 22, 18–22 (2006). https://doi.org/10.2165/00042310-200622040-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622040-00008

Search

Navigation